| Literature DB >> 24767830 |
Noy Ashkenazy1, Christopher R Henry2, Ashkan M Abbey3, Craig A McKeown1, Audina M Berrocal1, Timothy G Murray4.
Abstract
Juvenile xanthogranuloma (JXG) is an uncommon non-Langerhans cell histiocytic disorder that occurs predominantly in infants. Traditional treatment of ocular JXG involves the administration of topical or local corticosteroids. We treated 2 children with JXG refractory to local corticosteroid therapy with off-label intraocular bevacizumab. To our knowledge, this is the first report of successful use of bevacizumab for ocular JXG.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24767830 DOI： 10.1016/j.jaapos.2014.01.007
Source DB: PubMed Journal: J AAPOS ISSN： 1091-8531 Impact factor: 1.220